ALZAMEND NEURO, INC.
Moat Score — Alzamend Neuro, Inc.
Total Moat Score
4 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Alzamend holds patents on its proprietary lithium salt formulation and delivery approach, providing some intellectual property protection, though the underlying lithium mechanism itself is decades old and not novel. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a pre-revenue micro-cap biotech with no commercial manufacturing, Alzamend has no cost advantage and would face competition from inexpensive generic lithium products even if its formulation is eventually approved. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | With no approved product and generic lithium widely available at low cost, Alzamend would face significant pricing pressure unless it can prove a clear differentiated clinical benefit justifying premium branded pricing. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in small-molecule drug development; value is determined entirely by clinical data and regulatory outcomes. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | With no approved product on the market, Alzamend has no existing prescriber or patient base and therefore no switching-cost moat to speak of at this stage. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The neuropsychiatric and Alzheimer's treatment markets are large and support many competing approaches, so Alzamend gains little protection from efficient-scale dynamics as a micro-cap developer competing against both generics and well-funded large-pharma Alzheimer's programs. |